Philip Savage
Research Subjects
Philip Savage has a total of 532 co-authors. Here are the top co-authors by number of shared publications:
- Rosemary Ann Fisher
Department of Surgery and Cancer, Imperial College London, Charing Cross Hospital, London
23 shared publications - Neil James Sebire
Great Ormond Street Institute of Child Health, University College London, London, UK
20 shared publications - Michael J. Seckl
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom
18 shared publications Michael J. Seckl
Medical Oncology, Charing Cross Hospital, London, United Kingdom of Great Britain and Northern Ireland
15 shared publications- Justin Stebbing
Department of Surgery and Cancer, Imperial College London, London, United Kingdom
11 shared publications D Short
Department of Medical Oncology, Trophoblastic Tumour Screening and Treatment Centre, Charing Cross Hospital, Imperial Hospitals NHS Trust, London, UK
10 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Frontiers Media SA in Frontiers in Hematology
- Vol. 5, 1814036
The cells of origin of the chemotherapy-curable malignancies are highly sensitive to cytotoxic chemotherapy-mediated cell death
At present, the detailed mechanisms of how cytotoxic chemotherapy routinely produces cure in a limited number of malignancies whilst causing only more modest effects on the majority of cancers and healthy normal cells are uncertain. In this article, we reviewed published information regarding the impact of chemotherapy exposure on the viability of the cells of origin of a number of chemotherapy-curable malignancies. In general, these cells are difficult to study as they are transient, challenging to study ex vivo , and anatomically relatively inaccessible. In B-cell and T-cell acute lymphoblastic leukaemia, it is apparent that exposure to DNA damaging chemotherapy or radiotherapy results in near total loss of the respective cells of origin of pro-B cells and double-positive (DP) thymocytes within 2 days. However, these cells are rapidly replaced from the chemotherapy-resistant bone marrow stem cells. In diffuse large B-cell lymphoma, the germinal centre cells of origin are naturally poised on the edge of apoptosis, with a half-life of approximately 6 h, making in vitro study impractical. The probable cell of origin of testicular cancer is the OCT4 + stem cell, which shows similar sensitivity to chemotherapy to that of malignant cells, with total loss of these stem cells upon exposure to BEP (bleomycin, etoposide, and platinum/cisplatin) combination chemotherapy. Overall, it appears that chemotherapy-curable malignancies do not acquire a high degree of sensitivity to chemotherapy on their change to the malignant phenotype; rather, they maintain the high sensitivity of their cells of origin. These findings are in keeping with our previous observations that the high degree of chemotherapy sensitivity follows the dramatic changes in apoptotic sensitivity that accompany the genetic manipulations of variable–diversity–joining (VDJ) recombination, somatic hypermutation, meiosis, and nuclear fusion occurring in these normal healthy but transient cells.
- 10 June 2026
- Published by Frontiers Media SA in Frontiers in Hematology
- Vol. 5, 1814036
Open AccessThe cells of origin of the chemotherapy-curable malignancies are highly sensitive to cytotoxic chemotherapy-mediated cell death
At present, the detailed mechanisms of how cytotoxic chemotherapy routinely produces cure in a limited number of malignancies whilst causing only more modest effects on the majority of cancers and healthy normal cells are uncertain. In this article, we reviewed published information regarding the impact of chemotherapy exposure on the viability of the cells of origin of a number of chemotherapy-curable malignancies. In general, these cells are difficult to study as they are transient, challenging to study ex vivo , and anatomically relatively inaccessible. In B-cell and T-cell acute lymphoblastic leukaemia, it is apparent that exposure to DNA damaging chemotherapy or radiotherapy results in near total loss of the respective cells of origin of pro-B cells and double-positive (DP) thymocytes within 2 days. However, these cells are rapidly replaced from the chemotherapy-resistant bone marrow stem cells. In diffuse large B-cell lymphoma, the germinal centre cells of origin are naturally poised on the edge of apoptosis, with a half-life of approximately 6 h, making in vitro study impractical. The probable cell of origin of testicular cancer is the OCT4 + stem cell, which shows similar sensitivity to chemotherapy to that of malignant cells, with total loss of these stem cells upon exposure to BEP (bleomycin, etoposide, and platinum/cisplatin) combination chemotherapy. Overall, it appears that chemotherapy-curable malignancies do not acquire a high degree of sensitivity to chemotherapy on their change to the malignant phenotype; rather, they maintain the high sensitivity of their cells of origin. These findings are in keeping with our previous observations that the high degree of chemotherapy sensitivity follows the dramatic changes in apoptotic sensitivity that accompany the genetic manipulations of variable–diversity–joining (VDJ) recombination, somatic hypermutation, meiosis, and nuclear fusion occurring in these normal healthy but transient cells.
- 1 February 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (2) , 301-307
Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019
- 1 February 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (2) , 301-307
Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019
- Open Access
- 9 June 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 426
Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin
Cytotoxic DNA damaging chemotherapy brings clinical benefits in the treatment of many metastatic malignancies. However routine curative treatment remains restricted to a small number of malignancies including acute leukemia, high grade lymphoma, germ cell tumors, gestational malignancies and some of the rare childhood cancers. The detailed explanation for this dramatic divergence in outcomes remains to be elucidated. However, we have previously argued that there is a strong correlation between presence of the unique genetic events of immunoglobulin gene variable/diversity/joining (VDJ) recombination, somatic hypermutation (SHM), meiosis, nuclear fusion and gastrulation occurring in cells of origin of these malignancies and their high sensitivity to DNA damaging chemotherapy. In this study we have reviewed some of the basic physiological information relating to the specialized activity and sensitivity to DNA damage mediated apoptosis of normal cells undergoing these processes. In each of unique genetic events there are dramatic changes in apoptotic sensitivity. In VDJ recombination and somatic hypermutation over 95% of the cells involved undergo apoptosis, whilst in meiosis and nuclear fusion there are dramatic short term increases in the apoptotic sensitivity to DNA damage. It is apparent that each of the malignancies arising during these processes retains some of the unique phenotype associated with it. The impact of the physiological differences is most clearly seen in the two non-mutational malignancies. Gestational choriocarcinoma which arises shortly after nuclear fusion is routinely curable with chemotherapy whilst CIMP-positive ependymomas which is not linked to any of the unique genetic events is highly resistant. A similar pattern is found in a pair of malignancies driven by a single driver mutation. Infantile acute lymphoblastic leukemia (ALL) arises in a cell undergoing the early stages of VDJ recombination and has a 40% cure rate in contrast pediatric rhabdoid malignancy which is not linked to a unique genetic event responds very poorly to chemotherapy treatment. The physiological changes occurring in cancer cells at the time of the malignant transformation appear to have a major impact on the subsequent sensitivity to chemotherapy and curability. New therapies that impact on these pathways may be of therapeutic value.
- 9 June 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 426
Open AccessChemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin
Cytotoxic DNA damaging chemotherapy brings clinical benefits in the treatment of many metastatic malignancies. However routine curative treatment remains restricted to a small number of malignancies including acute leukemia, high grade lymphoma, germ cell tumors, gestational malignancies and some of the rare childhood cancers. The detailed explanation for this dramatic divergence in outcomes remains to be elucidated. However, we have previously argued that there is a strong correlation between presence of the unique genetic events of immunoglobulin gene variable/diversity/joining (VDJ) recombination, somatic hypermutation (SHM), meiosis, nuclear fusion and gastrulation occurring in cells of origin of these malignancies and their high sensitivity to DNA damaging chemotherapy. In this study we have reviewed some of the basic physiological information relating to the specialized activity and sensitivity to DNA damage mediated apoptosis of normal cells undergoing these processes. In each of unique genetic events there are dramatic changes in apoptotic sensitivity. In VDJ recombination and somatic hypermutation over 95% of the cells involved undergo apoptosis, whilst in meiosis and nuclear fusion there are dramatic short term increases in the apoptotic sensitivity to DNA damage. It is apparent that each of the malignancies arising during these processes retains some of the unique phenotype associated with it. The impact of the physiological differences is most clearly seen in the two non-mutational malignancies. Gestational choriocarcinoma which arises shortly after nuclear fusion is routinely curable with chemotherapy whilst CIMP-positive ependymomas which is not linked to any of the unique genetic events is highly resistant. A similar pattern is found in a pair of malignancies driven by a single driver mutation. Infantile acute lymphoblastic leukemia (ALL) arises in a cell undergoing the early stages of VDJ recombination and has a 40% cure rate in contrast pediatric rhabdoid malignancy which is not linked to a unique genetic event responds very poorly to chemotherapy treatment. The physiological changes occurring in cancer cells at the time of the malignant transformation appear to have a major impact on the subsequent sensitivity to chemotherapy and curability. New therapies that impact on these pathways may be of therapeutic value.
- 7 March 2020
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 127 (9) , 1102-1107
Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma: a UK population study
Objective: To investigate the demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma.Design: A retrospective national population‐based study.Setting: UK 1995–2015.Population: A total of 234 women with a diagnosis of gestational choriocarcinoma, in the absence of a prior molar pregnancy, managed at the UKs two gestational trophoblast centres in London and Sheffield.Methods: Retrospective review of the patient’s demographic and clinical data. Comparison with contemporary UK birth and pregnancy statistics.Main outcomes: Incidence statistics for non‐molar choriocarcinoma across the maternal age groups. Cure rates for patients by FIGO prognostic score group.Results: Over the 21‐year study period, there were 234 cases of non‐molar gestational choriocarcinoma, giving an incidence of 1:66 775 relative to live births and 1:84 226 to viable pregnancies. For women aged under 20, the incidence relative to viable pregnancies was 1:223 494, for ages 30–34, 1:80 227, and for ages 40–45, 1:41 718. Treatment outcomes indicated an overall 94.4% cure rate. Divided by FIGO prognostic groups, the cure rates were low‐risk group 100%, high‐risk group 96% and ultra‐high‐risk group 80.5%.Conclusions: Non‐molar gestational choriocarcinoma is a very rare diagnosis with little prior detailed information on the demographics and natural history. The data in this study give age‐related incidence data based on a large national population study. The results also demonstrated the widely varying natural history of this rare malignancy and the marked correlation of disease incidence with rising maternal age.Tweetable National gestational choriocarcinoma database indicates a close association between increasing maternal age and incidence.
- 7 March 2020
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 127 (9) , 1102-1107
Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma: a UK population study
Objective: To investigate the demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma.Design: A retrospective national population‐based study.Setting: UK 1995–2015.Population: A total of 234 women with a diagnosis of gestational choriocarcinoma, in the absence of a prior molar pregnancy, managed at the UKs two gestational trophoblast centres in London and Sheffield.Methods: Retrospective review of the patient’s demographic and clinical data. Comparison with contemporary UK birth and pregnancy statistics.Main outcomes: Incidence statistics for non‐molar choriocarcinoma across the maternal age groups. Cure rates for patients by FIGO prognostic score group.Results: Over the 21‐year study period, there were 234 cases of non‐molar gestational choriocarcinoma, giving an incidence of 1:66 775 relative to live births and 1:84 226 to viable pregnancies. For women aged under 20, the incidence relative to viable pregnancies was 1:223 494, for ages 30–34, 1:80 227, and for ages 40–45, 1:41 718. Treatment outcomes indicated an overall 94.4% cure rate. Divided by FIGO prognostic groups, the cure rates were low‐risk group 100%, high‐risk group 96% and ultra‐high‐risk group 80.5%.Conclusions: Non‐molar gestational choriocarcinoma is a very rare diagnosis with little prior detailed information on the demographics and natural history. The data in this study give age‐related incidence data based on a large national population study. The results also demonstrated the widely varying natural history of this rare malignancy and the marked correlation of disease incidence with rising maternal age.Tweetable National gestational choriocarcinoma database indicates a close association between increasing maternal age and incidence.
- Open Access
- 29 July 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
A case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations
Gestational choriocarcinoma is a rare malignancy believed to arise from the trophoblast cells of the placenta. Despite the frequently aggressive clinical nature, choriocarcinoma has been routinely curable with cytotoxic chemotherapy for over 50 years. To date little is known regarding the route to oncogenesis in this malignancy. In a case of intraplacental choriocarcinoma, we have performed detailed genetic studies including microsatellite analysis, whole genome sequencing (WGS) and methylation analysis of the tumour and surrounding mature placenta. The results of the WGS sequencing indicated a very low level of mutation and the absence of any driver mutations or oncogene activity in the tumour. The methylation analysis identified a distinctly different profile in the tumour from that of the mature placenta. Comparison with a panel of reference methylation profiles from different stages of placental development indicated that the tumour segregated with the first trimester samples. These findings suggest that gestational choriocarcinoma is likely to arise as a result of aberrations of methylation during development, rather than from DNA mutations. The results support the hypothesis that gestational choriocarcinoma arises from a normally transient early trophoblast cell. At this point in development this cell naturally has a phenotype of rapid division, tissue invasion and sensitivity to DNA damaging chemotherapy that is very similar to that of the mature choriocarcinoma cell.
- 29 July 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
Open AccessA case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations
Gestational choriocarcinoma is a rare malignancy believed to arise from the trophoblast cells of the placenta. Despite the frequently aggressive clinical nature, choriocarcinoma has been routinely curable with cytotoxic chemotherapy for over 50 years. To date little is known regarding the route to oncogenesis in this malignancy. In a case of intraplacental choriocarcinoma, we have performed detailed genetic studies including microsatellite analysis, whole genome sequencing (WGS) and methylation analysis of the tumour and surrounding mature placenta. The results of the WGS sequencing indicated a very low level of mutation and the absence of any driver mutations or oncogene activity in the tumour. The methylation analysis identified a distinctly different profile in the tumour from that of the mature placenta. Comparison with a panel of reference methylation profiles from different stages of placental development indicated that the tumour segregated with the first trimester samples. These findings suggest that gestational choriocarcinoma is likely to arise as a result of aberrations of methylation during development, rather than from DNA mutations. The results support the hypothesis that gestational choriocarcinoma arises from a normally transient early trophoblast cell. At this point in development this cell naturally has a phenotype of rapid division, tissue invasion and sensitivity to DNA damaging chemotherapy that is very similar to that of the mature choriocarcinoma cell.
- 7 April 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (1) , 93-98
The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014–2018
Drug treatment for cancer has changed dramatically over the past decade with many new drugs often with multiple applications. More recently, the detailed pathway for approval from the National Institute for Health and Care Excellence (NICE) in the UK has been simplified. To explore how these changes have impacted on systemic anti-cancer therapy tumour site-specific prescribing and workload activities, we have reviewed the prescribing records for 2014–2018 in a UK cancer network. Information about the numbers of new systemic anti-cancer therapy drugs and NICE approvals were obtained from print editions of the British National Formulary (BNF) and the NICE website. Data on the numbers of new chemotherapy courses and individual treatment-related attendances were obtained from the cancer network Chemocare electronic prescribing system. During the five-year study period, there were 49 new systemic anti-cancer therapy drugs for all tumour types, and a total of 65 NICE technology approvals for solid tumour indications. Overall numbers of treatment courses increased by 40.7% and total treatment-related visits by 80.6%. There was a wide variation across tumour types with the highest number of increased visits seen for melanoma (349.3%) and prostate cancer (242.3%), but in contrast, no appreciable increases were seen for lower gastrointestinal cancers or small cell lung cancer. The study confirms the major impact of the arrival of new drug technology and positive NICE appraisals on increasing systemic anti-cancer therapy prescribing and chemotherapy unit activity. The data in this study may be of help in planning for future service delivery planning and workforce configurations.
- 7 April 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (1) , 93-98
The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014–2018
Drug treatment for cancer has changed dramatically over the past decade with many new drugs often with multiple applications. More recently, the detailed pathway for approval from the National Institute for Health and Care Excellence (NICE) in the UK has been simplified. To explore how these changes have impacted on systemic anti-cancer therapy tumour site-specific prescribing and workload activities, we have reviewed the prescribing records for 2014–2018 in a UK cancer network. Information about the numbers of new systemic anti-cancer therapy drugs and NICE approvals were obtained from print editions of the British National Formulary (BNF) and the NICE website. Data on the numbers of new chemotherapy courses and individual treatment-related attendances were obtained from the cancer network Chemocare electronic prescribing system. During the five-year study period, there were 49 new systemic anti-cancer therapy drugs for all tumour types, and a total of 65 NICE technology approvals for solid tumour indications. Overall numbers of treatment courses increased by 40.7% and total treatment-related visits by 80.6%. There was a wide variation across tumour types with the highest number of increased visits seen for melanoma (349.3%) and prostate cancer (242.3%), but in contrast, no appreciable increases were seen for lower gastrointestinal cancers or small cell lung cancer. The study confirms the major impact of the arrival of new drug technology and positive NICE appraisals on increasing systemic anti-cancer therapy prescribing and chemotherapy unit activity. The data in this study may be of help in planning for future service delivery planning and workforce configurations.
- 28 December 2018
- Published by Taylor & Francis in Expert Opinion on Orphan Drugs
- Vol. 7 (1) , 27-36
Advances in current and emerging therapeutics for gestational trophoblast malignancies
Introduction: Gestational Trophoblastic Neoplasia (GTN) are a group of rare malignancies arising from the cells of conception. GTN was the first metastatic cancer to be cured with chemotherapy and nearly all of today’s patients can expect to be cured with modern drug treatment. Based on the experience of the GTN unit at Charing Cross Hospital in London, the historical, current and forthcoming management of this biologically unique malignancy will be reviewed. Areas covered: This review will cover the classification and epidemiology of molar pregnancies, gestational choriocarcinoma and PSTT/ETT. The current approaches to management for low, high and ultra high-risk patients and the recent impact of immunotherapy for chemotherapy resistant disease are discussed. Expert opinion: GTN form a group of rare but highly curable malignancies. The unique biology of the cancer cells makes them extremely sensitive to chemotherapy and also to immunotherapy and overall cure rates approach 100%. Optimising the organisation of care for this rare group of malignancies increases the cure rates and minimise adverse outcomes. Current immunotherapy research may allow patients to access curative treatment with lower toxicity and reduced long term side effects compared to prolonged treatment with cytotoxic drugs.
- 28 December 2018
- Published by Taylor & Francis in Expert Opinion on Orphan Drugs
- Vol. 7 (1) , 27-36
Advances in current and emerging therapeutics for gestational trophoblast malignancies
Introduction: Gestational Trophoblastic Neoplasia (GTN) are a group of rare malignancies arising from the cells of conception. GTN was the first metastatic cancer to be cured with chemotherapy and nearly all of today’s patients can expect to be cured with modern drug treatment. Based on the experience of the GTN unit at Charing Cross Hospital in London, the historical, current and forthcoming management of this biologically unique malignancy will be reviewed. Areas covered: This review will cover the classification and epidemiology of molar pregnancies, gestational choriocarcinoma and PSTT/ETT. The current approaches to management for low, high and ultra high-risk patients and the recent impact of immunotherapy for chemotherapy resistant disease are discussed. Expert opinion: GTN form a group of rare but highly curable malignancies. The unique biology of the cancer cells makes them extremely sensitive to chemotherapy and also to immunotherapy and overall cure rates approach 100%. Optimising the organisation of care for this rare group of malignancies increases the cure rates and minimise adverse outcomes. Current immunotherapy research may allow patients to access curative treatment with lower toxicity and reduced long term side effects compared to prolonged treatment with cytotoxic drugs.
- 12 November 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 16 (2) , 118-123
Enhanced Sensitivity of Lymphoid Cells to Ethanol ADH Acetaldehyde Toxicity; Implications for GDEPT and Adoptive T Cell Therapy
Background: The ability to kill lymphoid cells with a non-toxic prodrug/gene/ toxin system would be of value in the treatment of lymphoid malignancies and in the regulation of T cells used in adoptive immunotherapy Objective: In this in vitro study we examined the ability of a novel prodrug/gene/toxin system to produce cytotoxicity in lymphoid cells. The system uses a non-toxic prodrug ethanol, human alcohol dehydrogenase and exerts the toxic action via the prolonged production of acetaldehyde produced within targeted cells. Methods: Raji B cells were transduced with an alcohol dehydrogenase containing lentivirus and then exposed to differing durations of daily ethanol exposure. Cell numbers and viability were assessed by trypan blue exclusion. Results: Individually, ethanol and the ADH gene were non-toxic to Raji B cells. Exposure of ADH transduced cells to ethanol produced prompt growth inhibition and later cell killing that could be negated by the presence of 4-MP the alcohol dehydrogenase inhibitor. At 96 hours exposure to ethanol the number of ADH transduced cells had declined by up to 66% and their total number comprised only 2% of the proliferating untreated control cells Conclusion: The ethanol ADH acetaldehyde system offers a simple, safe, non-toxic approach to cancer therapy prodrug toxin technology. It may also offer a safe and non-toxic system to control the number and action of T cells used in adoptive immunotherapy.
- 12 November 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 16 (2) , 118-123
Enhanced Sensitivity of Lymphoid Cells to Ethanol ADH Acetaldehyde Toxicity; Implications for GDEPT and Adoptive T Cell Therapy
Background: The ability to kill lymphoid cells with a non-toxic prodrug/gene/ toxin system would be of value in the treatment of lymphoid malignancies and in the regulation of T cells used in adoptive immunotherapy Objective: In this in vitro study we examined the ability of a novel prodrug/gene/toxin system to produce cytotoxicity in lymphoid cells. The system uses a non-toxic prodrug ethanol, human alcohol dehydrogenase and exerts the toxic action via the prolonged production of acetaldehyde produced within targeted cells. Methods: Raji B cells were transduced with an alcohol dehydrogenase containing lentivirus and then exposed to differing durations of daily ethanol exposure. Cell numbers and viability were assessed by trypan blue exclusion. Results: Individually, ethanol and the ADH gene were non-toxic to Raji B cells. Exposure of ADH transduced cells to ethanol produced prompt growth inhibition and later cell killing that could be negated by the presence of 4-MP the alcohol dehydrogenase inhibitor. At 96 hours exposure to ethanol the number of ADH transduced cells had declined by up to 66% and their total number comprised only 2% of the proliferating untreated control cells Conclusion: The ethanol ADH acetaldehyde system offers a simple, safe, non-toxic approach to cancer therapy prodrug toxin technology. It may also offer a safe and non-toxic system to control the number and action of T cells used in adoptive immunotherapy.
- Open Access
- 1 February 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (2) , 254-257
What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients
- 1 February 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (2) , 254-257
Open AccessWhat is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients